- Medicon Valley
- News & Events
- News
- Events
- Medicon Valley Newsletter
- June 2008
- May 2008
- April 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- April 2007
- March 2007
- January 2007
- December 2006
- November 2006
- October 2006
- September 2006
- August 2006
- June 2006
- May 2006
- April 2006
- March 2006
- February 2006
- January 2006
- November 2005
- October 2005
- September 2005
- Business Opportunities
- Science & Research
- Networks
- Services & Support
- Companies & Institutions
- At Your Service
Medicon Valley Biomedical Newsletter
The Medicon Valley Biomedical Newsletter is intended for decision makers in pharmaceutical and biotech companies, investors and other professionals who wish to keep updated on business related activities in the Medicon Valley.
August
The Medicon Valley Biomedical Newsletter has changed format this month and reflects some of the changes planned to improve the newsletter. The top story this month is that the first lung transplant with incompatible blood types has been performed using Glycorex's Glycosorb-ABO. Find more information on this story and other top news from Medicon Valley in the newsletter below.
Other news from the region are continuously updated on our webpage: www.mediconvalley.com/NewsAndEvents/News
-
Glycorex’s Glycosorb-ABO Used to Complete Lung Transplant
24 Aug 2007
Glycorex Transplantation AB announces that the first lung transplantation with donor and recipient of different blood types has been completed using the company's product Glycosorb-ABO. ...
-
ViroGates Closes New Financing Round of EUR 2 million
31 Jul 2007
ViroGates A/S has closed a private financing round of EUR 2 million. In conjunction with the new investments, one of the largest Danish venture capital funds DTU Innovation/SEED Capital, who was one o...
-
Active Biotech's ANYARA Granted Orphan Drug Status by EMEA
30 Jul 2007
Active Biotech AB has announced that ANYARA has been granted Orphan Drug Status by the Committee for Orphan Medicinal Products of the European Medicines Agency, EMEA. Orphan Drug designation provides ...
-
New Centre for Epigenetics at University of Copenhagen
24 Aug 2007
The Centre for Epigenetics officially opened August 22, 2007 as a "Centre of Excellence" funded by The Danish National Research Foundation. The Centre brings together the distinct expertise of four re...
-
Research Grant for Cancer Gene Therapy
4 Aug 2007
Hans Skovgaard Poulsen, MD, DMSci, and his research team from Copenhagen University Hospital have developed an in vivo gene therapy against small cell lung cancer. They have obtained concept of proof ...
-
Genmab Regains Rights to HuMax-TAC
6 Aug 2007
Genmab A/S has announced that it has regained all rights to the HuMax-TAC antibody from Merck Serono following a portfolio review by Merck Serono. Worldwide rights to HuMax-TAC were previously license...
{FA3B697A-9438-4A93-8064-589B2DCAD36A}.pdf
Medicon Valley Biomedical Newsletter is published by
Region Skåne and Copenhagen Capacity.
We assist foreign companies in finding locations and partnerships in Medicon Valley. We offer free assistance at each step of the business development phase. Visit www.mediconvalley.com or contact us to learn more about the opportunities that await your company in Medicon Valley.
|
Copenhagen Capacity |
Region Skåne |
If you have any comments on the Medicon Valley Biomedical Newsletter please contact the editor at info@mediconvalley.com.
Here you can subscribe to the Medicon Valley Academy Newsletter
The MVA newsletter is an e-mail news service for Medicon Valley Academy (MVA) members and other actors within life science. The newsletter brings you information on new MVA initiatives and activities, editorials on issues of topical interest, news from the region together with available jobs and relevant life science events.
Click here to subscribe or visit www.mva.org.